<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170182</url>
  </required_header>
  <id_info>
    <org_study_id>7577/05-06</org_study_id>
    <nct_id>NCT01170182</nct_id>
  </id_info>
  <brief_title>Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition</brief_title>
  <official_title>A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck &amp; Co., Inc.,USA Under Fed Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the bioequivalence of Dr. Reddy's Omeprazole delayed release capsules
      under fed condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, two-treatment, two-period, two-sequence, single dose, crossover
      bioequivalence study to compare Omeprazole 40 mg Delayed Release Capsules (Dr. Reddy's
      Laboratories Ltd.,) with Prilosec® 40 mg (Omeprazole Delayed Release Capsules) (manufactured
      by Merck &amp; Co., Inc., USA) in 54 healthy, adult, human subjects under fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prilosec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prilosec® 40 mg Merck &amp; Co. Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole Delayed Release Capsules 40 mg</description>
    <arm_group_label>Omeprazole</arm_group_label>
    <other_name>Prelosec 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prilosec® 40 mg</intervention_name>
    <description>Prilosec® 40 mg</description>
    <arm_group_label>Prilosec</arm_group_label>
    <other_name>Omeprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who provided written informed consent.

          -  Subjects who were healthy within 18-45 years of age, weighing at least 50 kg.

          -  Body mass index of ≥18 kglm2 and ≤ 25 kg/m2, with body weight not less than 50 kg.

          -  Subjects with normal health as determined by medical history and physical examination
             performed within 15 days prior to the commencement of the study (dosing in period-I).

          -  Subjects with normal ECG, chest X-ray (PA view) and vital signs.

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj K Bose, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Limited, 142, IDA, Phase-II, Cherlapally, Hyderabad, India-500 051</affiliation>
  </overall_official>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>July 26, 2010</last_update_submitted>
  <last_update_submitted_qc>July 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assistant Manager - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited,</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

